Connect with us

Underwriter shortage slowing the pace of private-label deals

Loan underwriters are the chief cause of the RMBS logjam. They are in high demand for each stage of the mortgage process, yet they are in seriously short supply in a still-booming mortgage market. HW+ Premium Content
The post Underwriter shortage slowing.

Published

on

The supply-chain bottleneck afflicting the global economy has its own counterpart in the world of residential mortgage-backed securities, also referred to as RMBS.

One group of industry players — loan underwriters — are the chief cause of the logjam. They are in high demand for each stage of the mortgage process, yet they are in seriously short supply in a still-booming mortgage market. 

Underwriters are needed at the beginning of the process to conduct due diligence on mortgage originations, and they are in demand on the back-end of the pipeline to conduct due diligence on the loans being pooled and securitized in RMBS issuances sold to investors. 

With record mortgage production in recent years — some $8 trillion in total origination volume over the past two years, industry estimates show — and a resurgent private-label market this year, the pool of available underwriters has been stretched razor thin, according to executives with third-party due-diligence review (TPR) firms and bond-rating agencies interviewed for this story. 

About a half-dozen RMBS issuers also were contacted for this story, including J.P. Morgan, Goldman Sachs, Redwood Trust and United Wholesale Mortgage, as well as loan aggregator MAXEX, and all either declined comment or did not respond. The same was the case with industry groups and regulators like the Mortgage Bankers Association, the National Association of Mortgage Underwriters and the U.S. Securities and Exchange Commission.

The private label market share of U.S. mortgage securitizations reached 5% in 2019, then declined to 2.44% in 2020, largely because of the pandemic-spawned economic slowdown. In 2021, however, it has come roaring back, representing 3.53% of all securitizations over the first eight months of the year, according to a report by the Urban Institute’s Housing Policy Institute.

“Non-agency securitization has been rampant in the first eight months of 2021 [and continuing], totaling $89.79 billion, compared to $49.69 billion in the first eight months of 2019,” the report states.

Government-sponsored enterprises Fannie Mae and Freddie Mac, along with Ginnie Mae, collectively known as the agency market, account for the balance of residential mortgage-back security (RMBS) issuances. Prior to the Great Recession some 15 years ago, however, private-label securitizations were approaching 60% of the entire U.S. RMBS market.

The problem created by the current underwriter shortage is that, in some cases, it is creating backlogs for issuers seeking to have their securitization deals reviewed by bond-rating agencies who require that the loans in the pools for those transactions first be vetted by arms-length TPR firms.

“Many participants have said there’s been a problem [because of the underwriter shortage],” said Roelof Slump, managing director of U.S. RMBS at New York-based Fitch Ratings. “They can’t bring [securitization] deals to market as quickly. We certainly hear that as a concern in the market.”

Slump adds that it is not a new problem and “didn’t suddenly happen in October or November” of this year.

“It’s been an ongoing thing,” he said. “It’s like everybody is on the same highway and going the same speed, but we just recognize that it’s going to take longer to get there.”

John Toohig, managing director of whole loan trading at Raymond James in Memphis, described the dilemma as “a tremendous bottleneck,” adding that “it has to do with the third-party due-diligence providers who are the ones who have to kind of bless these deals, and there’s not enough underwriters out there [with those firms] to kind of push these deals through.”

“Over the course of the year, I’ve actually gotten a lot of phone calls from originators and issuers saying, ‘Listen, you know our deal is being held up by a third-party vendor, or underwriter, and it’s going to take them three months before they can bless our deal, so can you turn these loans faster [in the whole-loan trading market]?’”

The problem with delays, according to Joseph Mayhew, chief credit officer for Frisco, Texas-based Evolve Mortgage Services, which provides TPR services, is more acute for smaller or newer security issuers who don’t have established relationships with TPR firms that ensure due-diligence staff is dedicated year-round to handling a lender’s securitization volume.

“It depends on who you are,” Mayhew explained. “I’ve heard timeframes of up to three months [delay], but that might have been back in January to March of this year.”

He added that large issuers, such as big investment banks, “have a dedicated desk at their TPR firm [via contract], and they will sit there and wait for the loans, but they will not put anyone in front of them.”

So, the delays vary, with an average now of four-to-six weeks for smaller RMBS issuers that don’t have an ongoing contract relationship with a TPR firm. For those that do, it may take as little as two or three weeks, Mayhew said. 

“That’s from the time they submit a loan for TPR review to the time it comes out [of the review process],” he explained.

Michael Franco, CEO of SitusAMC, which is one of the larger TPR firms providing due-diligence services for private-label transactions, stressed that assessing the extent of the impact of the underwriter shortage and resulting delays falls into the realm of being “an unknown unknown, because you don’t really know who would have done a deal had the capacity been available.”

The underwriter shortage is even affecting the secondary market for mortgage-servicing rights (MSRs), Tom Piercy, managing director of Denver-based Incenter Mortgage Advisors, said. 

“They don’t underwrite every loan in an MSR trade,” he explained. “But they will go through anywhere from 5% to 10% of the bulk pool. … 

“There’s absolutely been cases where you’re hoping to close by a certain date, and it gets pushed out 30 days because of due diligence [needs]. …It is impacting every aspect of the market.”

Quantifying the nature of the underwriter shortage, beyond anecdotes from players in the industry, however, is not so simple. There is no entity tracking the shortage across the industry.

In fact, many firms have added staff over the past few years and still can’t keep up with the demand from a resurgent private-label market.

“If you simply look at the number of [RMBS] issuances that have been out there, the TPR firms have reviewed more loans this year than they did in prior years since the [global financial] crisis,” Fitch’s Slump said. “So, it may seem like they have reduced capacity, or reduced their ability to handle it, but they’ve actually ramped up.”

The U.S. Bureau of Labor Statistics does not have a job category set up solely for mortgage underwriters, but it does track job growth, or lack of it, in a category it calls “loan officers,” which includes underwriters as a subset. 

“Employment of loan officers is projected to show little or no change from 2020 to 2030,” the BLS’ Occupational Outlook for that job category states. “Despite limited employment growth, about 25,000 openings for loan officers are projected each year, on average, over the decade. Most of those openings are expected to result from the need to replace workers who transfer to different occupations or exit the labor force, such as to retire.”

The BLS outlook, among other factors, places the blame for the employment shortfall on “productivity-enhancing technology in loan processing [that is] expected to slow employment growth” despite increasing demand for “loan officers … to evaluate the creditworthiness of applicants and determine the likelihood that loans will be paid back in full and on time.”

Charlotte-based Canopy is a relative newcomer to the TPR market. The startup firm started doing business in the second quarter of this year. Despite that, its CEO, John Levonick, said “our phone has been ringing off the hook.”

“We’re all seasoned pros, but we’re still a brand-new company,” he said. “And for our phone to ring, presenting us with the opportunities that have been presented to us, reflects the state of the marketplace. Normally it would take a new due-diligence firm a year two or three to prove themselves.”

TPR firms are coping with the underwriter shortage in a number of ways, including recruiting, when possible, from local universities; expanding their use of automation and technology to reduce the need for human labor; and rethinking the division of labor in the underwriting process to improve efficiencies. And there has been an increased acceptance and reliance on statistical sampling methods for conducting due diligence on loan pools.

The practice of performing underwriting reviews on only samples of a loan pool slated for securitization is not knew, but Toohig of Raymond James says it’s increased use is linked to the underwriter shortage, “no doubt.”

“To do 100% due diligence on RMBS [private-label] securitizations is a lot of work that takes time and costs money for the issuer,” Slump said. “And things like loan sampling as opposed to 100% loan due diligence have been considered by issuers. 

“…There’s been a couple of issuers who have done that, but it’s not something that’s been universally used,” he added. “In certain cases, it can make a lot of sense — for example, with prime high-quality production, where the types of loans being originated and securitized are very uniform; the issuer has a history of their performance; the guidelines are very clear; and they [the loan pools] don’t have a lot of exceptions.”

Evolve’s Mayhew said he believes sampling is “reasonable.” 

“So somewhere in the 50% to 75% percent range [of loans sampled] is what most people I think are doing, but some of the smaller companies — the ones dealing with a lot of unique loan products — are doing 100%,” he added. “Sampling is really about when you think your data mostly looks the same, right? It’s not about when you think you’re going to have these weird outliers.”

Still, it’s an evolving market, and pressures build over time, creating new release valves to let some steam off the deadline and cost pressures. Jack Kahan, senior managing director of RMBS at New York-based Kroll Bond Rating Agency, points to “an example, and not the only one, of how RMBS issuers have been affected” by the underwriter shortage.

That example is from a presale report Kroll published for an RMBS nonprime RMBS transaction sponsored by Blue River Mortgage II LLC, which is backed by a pool of 610 non-qualified mortgages valued at $348 million. Blue River, according to the Kroll report, is owned by a fund managed by Angelo, Gordon & Co. LP — an asset-management firm with some $44 billion in assets under management.

“While 100% of the loans in the transaction are subject to third-party due-diligence review, 19% of the loans will not have such a review completed until up to 89 days following the closing of the transaction,” states the presale report, published in late September. “The sponsor will make representations and warranties that require the sponsor to repurchase any post-closing review loans that ultimately receive a grade of “C” or “D” — or do not receive a final grade. 

“The sponsor indicates that the post-close review mechanism is designed to mitigate the third-party review backlog being experienced at the time of launch of the transaction,” the report continues, “and should that TPR capacity improve, this mechanism may be discontinued for future issuance.”

Chris Guidici, managing director of business development at Wipro Opus Risk Solutions, an Illinois-based TPR firm, said normally the due diligence is done prior to a transaction closing, “but we have seen a shift with some [issuers] going to a post-diligence [review].”

Toohig of Raymond James added: “I don’t see much of that. I don’t even know how you can do that.”

This is the first story in a three-part series on the market-wide consequences of an underwriter shortage. The next two stories will drop later this week, so be sure to check back. 

The post Underwriter shortage slowing the pace of private-label deals appeared first on HousingWire.

Read More

Continue Reading

Uncategorized

PR55α-controlled PP2A Inhibits p16 Expression and Blocks Cellular Senescence Induction

“Our results show that PR55α specifically reduces p16 expression […]” Credit: 2024 Palanivel et al. “Our results show that PR55α specifically…

Published

on

“Our results show that PR55α specifically reduces p16 expression […]”

Credit: 2024 Palanivel et al.

“Our results show that PR55α specifically reduces p16 expression […]”

BUFFALO, NY- March 19, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 5, entitled, “PR55α-controlled protein phosphatase 2A inhibits p16 expression and blocks cellular senescence induction by γ-irradiation.”

Cellular senescence is a permanent cell cycle arrest that can be triggered by both internal and external genotoxic stressors, such as telomere dysfunction and DNA damage. The execution of senescence is mainly by two pathways, p16/RB and p53/p21, which lead to CDK4/6 inhibition and RB activation to block cell cycle progression. While the regulation of p53/p21 signaling in response to DNA damage and other insults is well-defined, the regulation of the p16/RB pathway in response to various stressors remains poorly understood. 

In this new study, researchers Chitra Palanivel, Lepakshe S. V. Madduri, Ashley L. Hein, Christopher B. Jenkins, Brendan T. Graff, Alison L. Camero, Sumin Zhou, Charles A. Enke, Michel M. Ouellette, and Ying Yan from the University of Nebraska Medical Center report a novel function of PR55α, a regulatory subunit of PP2A Ser/Thr phosphatase, as a potent inhibitor of p16 expression and senescence induction by ionizing radiation (IR), such as γ-rays. 

“During natural aging, there is a gradual accumulation of p16-expressing senescent cells in tissues [76]. To investigate the significance of PR55α in this up-regulation of p16, we compared levels of the p16 and PR55α proteins in a panel of normal tissue specimens derived from young (≤43 y/o) and old (≥68 y/o) donors.”

The results show that ectopic PR55α expression in normal pancreatic cells inhibits p16 transcription, increases RB phosphorylation, and blocks IR-induced senescence. Conversely, PR55α-knockdown by shRNA in pancreatic cancer cells elevates p16 transcription, reduces RB phosphorylation, and triggers senescence induction after IR. Furthermore, this PR55α function in the regulation of p16 and senescence is p53-independent because it was unaffected by the mutational status of p53. Moreover, PR55α only affects p16 expression but not p14 (ARF) expression, which is also transcribed from the same CDKN2A locus but from an alternative promoter. In normal human tissues, levels of p16 and PR55α proteins were inversely correlated and mutually exclusive. 

“Collectively, these results describe a novel function of PR55α/PP2A in blocking p16/RB signaling and IR-induced cellular senescence.”
 

Read the full paper: DOI: https://doi.org/10.18632/aging.205619 

Corresponding Authors: Michel M. Ouellette, Ying Yan

Corresponding Emails: mouellet@unmc.edu, yyan@unmc.edu

Keywords: p16, p14, CDKN2A locus, p53, RB, PR55α, PP2A, γ-irradiation

Click here to sign up for free Altmetric alerts about this article.

 

About Aging:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Facebook
  • X, formerly Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Reddit
  • Pinterest
  • Spotify, and available wherever you listen to podcasts

 

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Aging (Aging-US) Journal Office

6666 E. Quaker Str., Suite 1B

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 1

###


Read More

Continue Reading

Government

Bolsonaro Indicted By Brazilian Police For Falsifying Covid-19 Vaccine Records

Bolsonaro Indicted By Brazilian Police For Falsifying Covid-19 Vaccine Records

Federal police in Brazil have indicted former President Jair…

Published

on

Bolsonaro Indicted By Brazilian Police For Falsifying Covid-19 Vaccine Records

Federal police in Brazil have indicted former President Jair Bolsonaro for falsifying his Covid-19 vaccine card in order to travel to the United States and elsewhere during the pandemic.

Federal prosecutors will review the indictment and decide whether to pursue the case - which would be the first time the former president has faced criminal charges.

According to the indictment, Bolsonaro ordered a top deputy to obtain falsified Covid-19 vaccine records of himself and his 13-year-old daughter in late 2022, right before he flew to Florida for a three-month stay following his election loss.

Brazilian police are also waiting to hear back from the US DOJ on whether Bolsonaro used said cards to enter the United States, which would open him up to further criminal charges, the NY Times reports.

Bolsonaro has repeatedly claimed not to have received the Covid-19 vaccine, but denies any involvement in a plan to falsify his vaccination records. A previous investigation by Brazil's comptroller general concluded that Bolsonaro's vaccination records were false.

The records show that Bolsonaro, a COVID-19 skeptic who publicly opposed the vaccine, received a dose of the immunizer in a public healthcare center in Sao Paulo in July 2021. [ZH: hilarious, Reuters calling the vaccine an 'immunizer.']

The investigation concluded, however, that the former president had left the city the previous day and didn't leave Brasilia until three days later, according to a statement.

The nurse listed in the records as having applied the vaccine on Bolsonaro denied doing so and was no longer working at the center. The listed vaccine lot was also not available on that date, the comptroller general's office said. -Reuters

"It's a selective investigation. I'm calm, I don't owe anything," Bolsonaro told Reuters. "The world knows that I didn't take the vaccine."

During the pandemic, Bolsonaro panned the vaccine - and instead insisted on alternative treatments such as Ivermectin, which has antiviral properties against Covid-19. For this, he was investigated by Brazil's congress, which recommended that the former president be charged with "crimes against humanity," among other things, for his actions during the pandemic.

In May, Brazilian police raided Bolsonaro's home, confiscating his cell phone and arresting one of his closest aides and two of his security cards in connection to the vaccine record investigation.

Brazil's electoral court ruled that Bolsonaro can't run for public office until 2030 after he suggested that the country's voting system was rigged. For that, he has to sit out the 2026 election.

Tyler Durden Tue, 03/19/2024 - 11:00

Read More

Continue Reading

Spread & Containment

TJ Maxx and Marshalls follow Costco and Target on upcoming closures

Many of these stores have information customers need to know.

Published

on

U.S. consumers have come to increasingly rely on the near ubiquity of convenience stores and big-box retailers. 

Many of us depend on these stores being open practically all day, every day, even during some of the biggest holidays. After all, Black Friday beckons retail stores to open just hours after a Thanksgiving Day dinner in hopes of attracting huge crowds of shoppers in search of early holiday sales. 

Related: Walmart announces more store closures for 2024

And it's largely true that before the covid pandemic most of our favorite stores were open all the time. Practically nothing — from inclement weather to bad news to holidays — could shut down a major operation like Walmart  (WMT)  or Target  (TGT)

Then the pandemic hit, and it turned everything we thought we knew about retail operations upside down. 

Everything from grocery stores to shopping malls shut down in an effort to contain potential spread. And when they finally reopened to the public, different stores took different precautionary measures. Some monitored how many shoppers were inside at once, while others implemented foot-traffic rules dictating where one could enter and exit an aisle. And almost every one of them mandated wearing masks at one point or another. 

Though these safety measures seem like a distant memory, one relic from the early 2020s remains firmly a part of our new American retail life. 

A woman in a face mask shopping in the HomeGoods kitchen aisle.

Jeff Greenberg/Getty Images

Store closures announced for spring 2024

Many retailers have learned to adapt after a volatile start to this third decade, and in many ways this requires serving customers better and treating employees better to retain a workforce. 

In some cases, the changes also reflect a change in shopping behavior, as more customers order online and leave more breathing room for brick-and-mortar operations. This also means more time for employees. 

Thanks to this, big retailers have recently changed how they operate, especially during holiday hours, with Walmart recently saying it would close during Thanksgiving to give employees more time to spend with loved ones.

"I am delighted to share that once again, we'll be closing our doors for Thanksgiving this year," Walmart U.S. CEO John Furner told associates in a video posted to Twitter in November. "Thanksgiving is such a special day during a very busy season. We want you to spend that day at home with family and loved ones." 

Other retailers have now followed suit, with Costco  (COST) , Aldi, and Target all saying they would close their doors for 24 hours on Easter Sunday, March 31. 

Now, the stores that operate under TJX Cos.  (TJX)  will also shut down during the holiday, including HomeGoods, TJ Maxx and Marshalls

Though it closed on Thanksgiving, Walmart says it will remain open for shoppers on Easter. 

Here's a list of stores that are closing for Easter 2024: 

  • Target
  • Costco
  • Aldi
  • TJ Maxx
  • Marshalls
  • HomeGoods
  • Publix
  • Macy's
  • Best Buy
  • Apple
  • ACE Hardware

Others are expected to remain open, including:

  • Walmart
  • Ikea
  • Petco
  • Home Depot

Most of the stores closing on Sunday will reopen for regular business hours on Monday. 

Read More

Continue Reading

Trending